Patents by Inventor Mark Baer

Mark Baer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PRODUCTION OF FLU VACCINE IN MYCELIOPHTHORA THERMOPHILA
    Publication number: 20230346913
    Abstract: Recombinant expression of influenza virus surface proteins in the fungus Myceliophthora thermophila strain C1 is provided. The recombinant proteins are for use in influenza vaccine compositions.
    Type: Application
    Filed: July 11, 2023
    Publication date: November 2, 2023
    Applicant: DYADIC INTERNATIONAL INC.
    Inventors: Mark EMALFARB, Teunis Cornelis Verwoerd, Mark R. Alfenito, Mark Baer, Isabelle Legastelois, Marie-Pierre Kazek, Marie-Clotilde Bernard, Jean Dubayle, Richard Kensinger
  • Production of flu vaccine in
    Patent number: 11738080
    Abstract: Recombinant expression of influenza virus surface proteins in the fungus Myceliophthora thermophila strain C1 is provided. The recombinant proteins are for use in influenza vaccine compositions.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: August 29, 2023
    Assignee: DYADIC INTERNATIONAL INC.
    Inventors: Mark Emalfarb, Teunis Cornelis Verwoerd, Mark R. Alfenito, Mark Baer, Isabelle Legastelois, Marie-Pierre Kazek, Marie-Clotilde Bernard, Jean Dubayle, Richard Kensinger
  • PRODUCTION OF FLU VACCINE IN MYCELIOPHTHORA THERMOPHILA
    Publication number: 20200215183
    Abstract: Recombinant expression of influenza vims surface proteins in the fungus Myceliophthora thermophila strain Cl is provided. The recombinant proteins are for use in influenza vaccine compositions.
    Type: Application
    Filed: August 9, 2018
    Publication date: July 9, 2020
    Inventors: Mark EMALFARB, Teunis Cornelis VERWOERD, Mark R. ALFENITO, Mark BAER, Isabelle LEGASTELOIS, Marie-Pierre KAZEK, Marie-Clotilde BERNARD, Jean DUBAYLE, Richard KENSINGER
  • Influenza vaccine and therapy
    Patent number: 10080792
    Abstract: The present invention is directed generally to M1 polypeptides that can be utilized as vaccines and/or antigens for generation of anti-M1 polypeptide antibodies for prophylactic treatment of individuals who are susceptible to infection by influenza virus. The anti-M1 polypeptide antibodies of the invention are useful for treatment of individuals infected with influenza virus, or useful for prophylactic treatment of individuals who are susceptible to infection by influenza virus, or for immune-suppressed individuals who cannot generate an effective antibody response.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: September 25, 2018
    Assignee: EnGen Bio, Inc.
    Inventors: Mark Alfenito, Mark Baer, Doris Bucher, Geoffrey Yarranton
  • Influenza vaccine and therapy
    Patent number: 9999662
    Abstract: The present invention is directed generally to M1 polypeptides that can be utilized as vaccines and/or antigens for generation of anti-M1 polypeptide antibodies for prophylactic treatment of individuals who are susceptible to infection by influenza virus. The anti-M1 polypeptide antibodies of the invention are useful for treatment of individuals infected with influenza virus, or useful for prophylactic treatment of individuals who are susceptible to infection by influenza virus, or for immune-suppressed individuals who cannot generate an effective antibody response.
    Type: Grant
    Filed: September 21, 2014
    Date of Patent: June 19, 2018
    Assignee: EnGen Bio, Inc.
    Inventors: Mark R. Alfenito, Mark Baer, Doris Bucher
  • Detection of EphA3 as a Marker of the Presence of a Solid Tumor
    Publication number: 20170335001
    Abstract: The invention provides methods and compositions for detecting non-hematopoietic, non-tumor EphA3-expressing cells in cancer patients and for monitoring the prognosis of patients using EphA3.
    Type: Application
    Filed: July 8, 2016
    Publication date: November 23, 2017
    Inventors: Martin Lackmann, Andrew Mark Scott, Catherine To, Christopher R. Bebbington, Geoffrey T. Yarranton, Mark Baer, Varghese Palath
  • Influenza Vaccine and Therapy
    Publication number: 20170035876
    Abstract: The present invention is directed generally to M1 polypeptides that can be utilized as vaccines and/or antigens for generation of anti-M1 polypeptide antibodies for prophylactic treatment of individuals who are susceptible to infection by influenza virus. The anti-M1 polypeptide antibodies of the invention are useful for treatment of individuals infected with influenza virus, or useful for prophylactic treatment of individuals who are susceptible to infection by influenza virus, or for immune-suppressed individuals who cannot generate an effective antibody response.
    Type: Application
    Filed: September 22, 2016
    Publication date: February 9, 2017
    Applicant: EnGen Bio, LLC
    Inventors: Mark Alfenito, Mark Baer, Doris Bucher, Geoffrey Yarranton
  • Methods of Treating Hematological Proliferative Disorders by Targeting EphA3 Expressed on Aberrant Vasculature in Bone Marrow
    Publication number: 20150329647
    Abstract: The invention provides diagnostic and therapeutic methods for the treatment of hematological proliferative disorders.
    Type: Application
    Filed: July 30, 2015
    Publication date: November 19, 2015
    Inventors: Geoffrey T. Yarranton, Varghese Palath, Christopher R. Bebbington, Mark Baer
  • Methods of treating hematological proliferative disorders by targeting EphA3 expressed on aberrant vasculature in bone marrow
    Patent number: 9109032
    Abstract: The invention provides diagnostic and therapeutic methods for the treatment of hematological proliferative disorders.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: August 18, 2015
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Geoffrey T. Yarranton, Varghese Palath, Christopher R. Bebbington, Mark Baer
  • Anti-EMR1 antibodies
    Patent number: 9045539
    Abstract: The invention provides anti-EGF-like module containing, mucin-like, hormone receptor-like 1 (EMR1) antibodies and methods of using such antibodies to treat EMR1-related diseases.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: June 2, 2015
    Assignee: Kalobios Pharmaceuticals, Inc.
    Inventors: Kenneth Luehrsen, Mark Baer, Christopher R. Bebbington, David Martinez, Varghese Palath, Swathi Sujatha-Bhaskar, Nenad Tomasevic, Jason Williams, Geoffrey T. Yarranton
  • INFLUENZA VACCINE AND THERAPY
    Publication number: 20150086560
    Abstract: The present invention is directed generally to M1 polypeptides that can be utilized as vaccines and/or antigens for generation of anti-M1 polypeptide antibodies for prophylactic treatment of individuals who are susceptible to infection by influenza virus. The anti-M1 polypeptide antibodies of the invention are useful for treatment of individuals infected with influenza virus, or useful for prophylactic treatment of individuals who are susceptible to infection by influenza virus, or for immune-suppressed individuals who cannot generate an effective antibody response.
    Type: Application
    Filed: September 21, 2014
    Publication date: March 26, 2015
    Inventors: Mark R. AIfenito, Mark Baer, Doris Bucher
  • ANTIBODIES TO THE PCRV ANTIGEN OF PSEUDOMONAS AERUGINOSA
    Publication number: 20150030614
    Abstract: The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.
    Type: Application
    Filed: October 8, 2014
    Publication date: January 29, 2015
    Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton, Mark Baer
  • Antibodies to the PcrV antigen of
    Patent number: 8877191
    Abstract: The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.
    Type: Grant
    Filed: October 11, 2011
    Date of Patent: November 4, 2014
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton, Mark Baer
  • ANTI-EMR1 ANTIBODIES
    Publication number: 20130064826
    Abstract: The invention provides anti-EMR1 antibodies and methods of using such antibodies to treat EMR1-related diseases.
    Type: Application
    Filed: May 25, 2012
    Publication date: March 14, 2013
    Inventors: Kenneth Luehrsen, Mark Baer, Christopher R. Bebbington, David Martinez, Varghese Palath, Swathi Sujatha-Bhaskar, Nenad Tomasevic, Jason Williams, Geoffrey T. Yarranton
  • METHODS OF TREATING HEMATOLOGICAL PROLIFERATIVE DISORDERS BY TARGETING EPHA3 EXPRESSED ON ABERRANT VASCULATURE IN BONE MARROW
    Publication number: 20130039907
    Abstract: The invention provides diagnostic and therapeutic methods for the treatment of hematological proliferative disorders.
    Type: Application
    Filed: August 10, 2012
    Publication date: February 14, 2013
    Applicant: KaloBios Pharmaceuticals Inc.
    Inventors: Geoffrey T. Yarranton, Varghese Palath, Christopher R. Bebbington, Mark Baer
  • Antibodies to the PcrV Antigen of Pseudomonas aeruginosa
    Publication number: 20120020986
    Abstract: The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.
    Type: Application
    Filed: October 11, 2011
    Publication date: January 26, 2012
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton, Mark Baer
  • DETECTION OF EPHA3 AS A MARKER OF THE PRESENCE OF A SOLID TUMOR
    Publication number: 20110318304
    Abstract: The invention provides methods and compositions for detecting non-hematopoietic, non-tumor EphA3-expressing cells in cancer patients and for monitoring the prognosis of patients using EphA3.
    Type: Application
    Filed: June 20, 2011
    Publication date: December 29, 2011
    Inventors: Martin Lackmann, Andrew Mark Scott, Catherine To, Christopher R. Bebbington, Geoffrey T. Yarranton, Mark Baer, Varghese Palath
  • Antibodies to the PcrV antigen of
    Patent number: 8044181
    Abstract: The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.
    Type: Grant
    Filed: December 1, 2008
    Date of Patent: October 25, 2011
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton, Mark Baer
  • COMBINATION ANTIBIOTIC AND ANTIBODY THERAPY FOR THE TREATMENT OF PSEUDOMONAS AERUGINOSA INFECTION
    Publication number: 20100272736
    Abstract: The present invention provides improved pharmaceutical compositions and methods of treating or preventing development of bacteremia associated with Pseudomonas aeruginosa infections, where the method comprises administering an antibiotic and an anti-PcrV antibody.
    Type: Application
    Filed: February 4, 2010
    Publication date: October 28, 2010
    Applicants: KaloBios Pharmaceuticals, Inc., The Regents of the University of California
    Inventors: Mark Baer, Christopher R. Bebbington, Geoffrey T. Yarranton, Susan Lynch, Yuanlin Song
  • Antibodies to the PcrV Antigen of Pseudomonas aeruginosa
    Publication number: 20090191186
    Abstract: The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.
    Type: Application
    Filed: December 1, 2008
    Publication date: July 30, 2009
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton, Mark Baer